Lanxin Li - Publications

p53: A player in the tumor microenvironment.

Journal: Oncology research

Published: August 14, 2024

Cytotoxicity and inhibitory potential of CUDC-101 in non-small cell lung cancer cells with rare EGFR L861Q mutation.

Journal: Current research in toxicology

Published: June 08, 2024

A novel role for WZ3146 in the inhibition of cell proliferation via ERK and AKT pathway in the rare EGFR G719X mutant cells.

Journal: Scientific reports

Published: May 29, 2024

Almonertinib and alflutinib show novel inhibition on rare EGFR S768I mutant cells.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: February 01, 2024

BDTX-189, a novel tyrosine kinase inhibitor, inhibits cell activity via ERK and AKT pathways in the EGFR C797S triple mutant cells.

Journal: Chemico-biological interactions

Published: January 28, 2024

Correction to: Sensitivity analysis of EGFR L861Q mutation to six tyrosine kinase inhibitors.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: November 20, 2023

CUDC‑101 is a potential target inhibitor for the EGFR‑overexpression bladder cancer cells.

Journal: International journal of oncology

Published: May 19, 2023

Six first-line tyrosine kinase inhibitors reveal novel inhibition potential for the EGFR S768I mutation.

Journal: Toxicology and applied pharmacology

Published: July 29, 2022

Sensitivity analysis of EGFR L861Q mutation to six tyrosine kinase inhibitors.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: February 05, 2022